Privacy Policy

Oscient Pharmaceuticals Corporation, its subsidiaries and affiliates (collectively, "Oscient" or "we") are committed to maintaining the privacy and accuracy of your personal information and to protecting such information from loss, misuse, unauthorized access, alteration, and destruction. Please read this Privacy Policy carefully to understand how your personal information will be treated as you use our website. This Policy may change from time to time, so please check back periodically.

Collection and Use of Personal Information

When you visit this website, we do not collect any personally identifiable information without your consent. Oscient will only collect, store, and/or use personally identifiable information, such as name, address, telephone number, e-mail address, or other information, when you voluntarily submit it to us; for example, when you inquire about our products or services, or otherwise request information from us. We may use this personally identifiable information to respond to your inquiries or to personalize the information we provide to you.

In general, Oscient does not sell or share personally identifiable information with third parties. Personal information about you will only be used and disclosed by Oscient or those working on its behalf to respond to your inquiries or otherwise provide you with updated information about products or services that may be of interest to you. You may elect not to have your personal information used for these purposes by contacting Oscient. Personally identifiable information may also be disclosed without your knowledge or consent, but only to the extent required by law, legal process, or for the purposes of a government investigation; to protect and defend the rights or property of Oscient; or in an emergency threatening an individual's life, health, or security.

In the event you contact Oscient regarding your experience in using an Oscient product we may use such information in reports Oscient submits to the Federal Food and Drug Administration. We may also use the information to follow up regarding an unexpected event involving the use of an Oscient product.

Except under the limited circumstances described above, Oscient will not sell, rent, or disclose personally identifiable information to any third party without your permission.

Cookies

Cookies are small text files that a website stores on a user's computer hard drive. Cookies contain non-personally identifiable information about the user that can be retrieved at a later time to make the user's future visits to the website more efficient. Cookies are used by many websites.

We may use cookies to enhance your experience on this site by delivering content specific to your interests and preferences. You may delete or decline the cookie using the tools in your web browser. Although you may still use our site without the cookie, some parts of the site may not work properly for you.

Collection and Use of Non-Personal Information

Oscient may automatically collect non-personally identifiable information relating to such matters as the total number of visits to our website, the number of visitors to each page of our website, the Internet Protocol (IP) addresses of our visitors, and the time spent on our website. We may use this information, which is collected in and remains in aggregate form, to understand how our visitors use our website so that we can improve it. We may also use your IP address to help diagnose problems with our servers and for purposes of system administration. From time to time, we may share aggregated, non-personally identifiable information with our agents, business partners, consultants, or other third parties.

Minors

Oscient does not knowingly collect or use personally identifiable information from anyone under the age of 18, nor do we market our site to minors.

Security

Although we have tried to create a safe and reliable site, the confidentiality of any information transmitted to or from this site cannot be guaranteed. Always exercise caution when conveying personal information over the Internet. When disclosing any personal information, remain mindful that such information might be accessible by the public and, consequently, may be collected and used by others without your consent. Your use of the Internet and this site is solely at your own risk.

Links

Oscient may provide links from this website to other websites maintained by independent third parties. This privacy policy applies solely to the information collected on this website. We are not responsible for the privacy practices of independent third parties. We encourage you to be aware when you leave this site and to read the privacy policies of any other websites that you may visit.

Contact Us

If you have questions regarding our privacy practices, you may contact us at:

OSCIENT PHARMACEUTICALS CORPORATION

Attn: Legal Department
1000 Winter Street
Suite 2200
Waltham, MA 02451
781-398-2300

| | | | |

Important Safety Information

ANTARA® (fenofibrate) capsules is contraindicated in patients with hypersensitivity to fenofibrate, in patients with hepatic or severe renal dysfunction including primary biliary cirrhosis, in patients with unexplained persistent liver function abnormality, and in patients with preexisting gallbladder disease.
Fenofibrate has been associated with increases in serum transaminases. Regular periodic monitoring of liver function should be performed, for duration of therapy, and therapy discontinued if enzyme levels persist above 3 times the normal limit.
There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (eg, >2000 mg/dL) may increase the risk of developing pancreatitis. ANTARA therapy on reducing this risk has not been studied.
Fenofibrate may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, ANTARA therapy should be discontinued.
The combined use of ANTARA and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk. The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated with rhabdomyolysis, markedly elevated creatine kinase levels, and myoglobinuria, leading to acute renal failure.
The use of fibrates alone including ANTARA, may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Patients complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy. Discontinue ANTARA if myopathy or myositis is suspected or diagnosed.
The effect of ANTARA on coronary heart disease morbidity and mortality and noncardiovascular mortality has not been established.
Patients treated with other fibrate drugs experienced an increase in noncardiovascular and cardiovascular morbidity and mortality compared with placebo-treated patients.
Other precautions include pancreatitis, hypersensitivity reactions, and hematologic changes. Refer to full Prescribing Information for a complete list of precautions.
Caution should be exercised when coumarin anticoagulants are given in conjunction with ANTARA. The dosage of the anticoagulants should be reduced to maintain the prothrombin time/INR at the desired level to prevent bleeding complications. Frequent prothrombin time/INR determinations are advisable until it has been definitely determined that the prothrombin time/INR has stabilized.
Since bile acid sequestrants may bind other drugs given concurrently, patients should take ANTARA at least 1 hour before or 4–6 hours after a bile acid binding resin to avoid impeding its absorption.
Cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine. Because renal excretion is the primary elimination route of fibrate drugs including ANTARA, there is a risk that an interaction will lead to deterioration. The benefits and risks of using ANTARA with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and lowest effective dose employed.
Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.
The most common (≥2% reported in clinical trials) side effects are: abnormal liver function test, including increased AST; increased ALT; CPK increase; respiratory disorder; abdominal pain; back pain; headache; diarrhea; nausea; rhinitis; asthenia; flu syndrome and constipation.

Please see full Prescribing Information.

This Web site and the information contained herein is intended for use by US residents only.